If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-20. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Galactose oxidase (D-galactose:oxygen 6-oxidoreductase, D-galactose oxidase, beta-galactose oxidase; abbreviated GAO, GAOX, GOase; EC 1.1.3.9) is an enzyme that catalyzes the oxidation of D-galactose in some species of fungi. Galactose oxidase belongs to the family of oxidoreductases. Copper ion is required as a cofactor for galactose oxidase. A remarkable feature of galactose oxidase is that it is a free radical enzyme. Its catalytic site contains a free radical ligand coordinating to the copper center. This free radical ligand is a covalently cross-linked cysteine and tyrosine side chains that is formed during post-translational modification.
=== Pre-industrial technology === Nanoparticles were used by artisans since prehistory, albeit without knowledge of their nature. They were used by glassmakers and potters in Classical Antiquity, as exemplified by the Roman Lycurgus cup of dichroic glass (4th century CE) and the lusterware pottery of Mesopotamia (9th century CE). The latter is characterized by silver and copper nanoparticles dispersed in the glassy glaze.
With the recent advances of noninvasive imaging, living liver donors usually have to undergo imaging examinations for liver anatomy to decide if the anatomy is feasible for donation. The evaluation is usually performed by multidetector row computed tomography (MDCT) and magnetic resonance imaging (MRI). MDCT is good in vascular anatomy and volumetry. MRI is used for biliary tree anatomy. Donors with very unusual vascular anatomy, which makes them unsuitable for donation, could be screened out to avoid unnecessary operations.
On December 4, 2020, Pritzker announced that Illinois would receive 109,000 initial doses of Pfizer's COVID-19 vaccine once the U.S. Food and Drug Administration approved the vaccine. On February 26, 2021, Pritzker, Cook County Board president Toni Preckwinkle, Chicago mayor Lori Lightfoot, U.S. senators Dick Durbin and Tammy Duckworth, and the Biden administration announced that eligible Illinoisans could get vaccinated starting March 10 at a new mass vaccination site at the United Center. On July 29, 2021, Pritzker announced that everyone who enters a state building was required to wear a face mask regardless of vaccination status. On August 5, 2021, Pritzker announced that face masks must be worn at all times while inside P-12 schools, daycares, and long-term care facilities regardless of vaccination status. He also announced that face masks were required for all P-12 indoor sports, and that all state employees in congregate facilities must be vaccinated by October 4. On August 26, 2021, Pritzker announced that beginning on August 30, a statewide indoor mask mandate would be reimposed to handle the surge caused by the Delta variant. He also announced a vaccine mandate for all education employees in P-12 and higher education statewide and for all higher education students and healthcare workers. Pritzker announced that anyone who did not get a COVID-19 vaccine by September 5 would have to do weekly COVID testing. On September 19, 2021, Pritzker began imposing a COVID-19 vaccine mandate for college students, educators and most health care workers.
=== Operation Freedom's Sentinel === The 1st BCT deployed to Afghanistan in support of Operation Freedom's Sentinel from June 2017 to March 2018. Two soldiers were killed in action when their convoy was purposefully hit by a vehicle filled with explosives. The 3rd BCT deployed to Afghanistan in support of Operation Freedom's Sentinel from July 2019 to March 2020. In February 2020 soldiers from the 1st BCT, 10th Mountain Division were deployed to Afghanistan to replace the 3rd BCT as part of a unit rotation.
Sources: en.wikipedia.org
A refrigeration system meant to cool tanks containing liquid MIC had been shut down in January 1982 and the freon had been removed in June 1984. Since the MIC storage system assumed refrigeration, its high temperature alarm, set to sound at 11 °C (52 °F) had long since been disconnected, and tank storage temperatures ranged between 15 °C (59 °F) and 40 °C (104 °F) A flare tower to burn the MIC gas as it escaped, which had had a connecting pipe removed for maintenance, was improperly sized to neutralise a leak of the size produced by tank E610. A vent gas scrubber which had been deactivated at the time and was in 'standby' mode, and similarly had insufficient caustic soda and power to safely stop a leak of the magnitude produced. About 30 tonnes of MIC escaped from the tank into the atmosphere in 45 to 60 minutes. This would increase to 40 tonnes within two hours. The gases were blown in a southeast direction over Bhopal. A UCIL employee triggered the plant's alarm system at 12:50 a.m. as the concentration of gas in and around the plant became difficult to tolerate. Activation of the system triggered two siren alarms: one that specifically sounded inside the UCIL plant itself and a second directed to the exterior which would alert the general public and the city of Bhopal. The two siren systems had been decoupled from one another in 1982, so that it was possible to leave the factory warning siren on while the public one remained inactive. This is what had occurred; the public siren briefly sounded at 12:50 a.m.
==== Absorption ==== With oral administration of a single dose, THC is almost completely absorbed by the gastrointestinal tract. However, due to first-pass metabolism in the liver and the high lipid solubility of THC, only about 5 to 20% reaches circulation. Following oral administration, concentrations of THC and its major active metabolite 11-hydroxy-THC (11-OH-THC) peak after 0.5 to 4 hours, with median time to peak of 1.0 to 2.5 hours at different doses. In some cases, peak levels may not occur for as long as 6 hours. Concentrations of THC and 11-hydroxy-THC in the circulation are approximately equal with oral administration. There is a slight increase in dose proportionality in terms of peak and area-under-the-curve levels of THC with increasing oral doses over a range of 2.5 to 10 mg. A high-fat meal delays time to peak concentrations of oral THC by 4 hours on average and increases area-under-the-curve exposure by 2.9-fold, but peak concentrations are not significantly altered. A high-fat meal additionally increases absorption of THC via the lymphatic system and allows it to bypass first-pass metabolism. Consequently, a high-fat meal increases levels of 11-hydroxy-THC by only 25% and most of the increase in bioavailability is due to increased levels of THC. The bioavailability of THC when smoking or inhaling is approximately 25%, with a range of 2% to 56% (although most commonly between 10–35%).
Another example is Girgui at Harvard University, who built a MMS based on existing underwater mass spectrometers (UMS) that can operate underwater to study the influence of microbes on the methane and hydrogen content of the ocean. He worked with a mechanical engineer to package a commercial quadrupole mass analyzer from Stanford Research Systems, a Pfeiffer HiPace80 turbopump, and a custom gas extractor into a 25 cm × 90 cm cylinder. Total cost is about $15,000. The Analytical Instrumentation Research Institute in Korea also developed a palm-portable mass spectrometer. The size and weight is reduced to 1.54 L and 1.48 kg respectively, and it used 5 W power only. The PPMS is based on four parallel disk ion traps, a small ion getter pump and a micro-computer. The PPM can perform the scan ion mass of up to m/z 300 and detect the ppm concentration of organic gases diluted in the air. The Harsh-Environment Mass Spectrometry Society is holding a biannual workshop that focuses on in-situ mass spectrometry in extreme environments, such as in the deep ocean, volcano crater, or outer space require high reliability, autonomous or remote operation, ruggedness with minimum size, weight, and power. The archives of the workshop include ~100 presentations focusing on the design and application of miniature mass spectrometers.
== History == Lamivudine/zidovudine (brand name Combivir) was introduced to the market with FDA approval in 1997. Its impact in history is significant as it was the first combination therapy with a fixed dose for HIV-positive people, and soon solidified its title as a gold standard as it was the most prescribed NRTI in initial HIV treatment for newly diagnosed patients. The arrival of Combivir was seen as a new revolution in HIV therapy, with its improved toxicity profile and tolerability, especially compared to the undesirable side effects of lone AZT therapy or the unfavorable facial and lipoatrophy seen in Stavudine monotherapy at that time.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.